Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo

Neuropharmacology

Volumn 40, Issue 8, 2001, Pages 1003-1009

  Vandergriff, Jim ^a   Huff, Keith ^a   Bond, Ann ^a   Lodge, David ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

AMPA receptors; Hippocampal neurones; LY392098; LY404187; Spinal neurones; Synaptic excitation

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; GLUTAMATE RECEPTOR; KETAMINE; LY 392098; LY 404187; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; FEMALE; FOLLOW UP; HIPPOCAMPUS; MALE; MENTAL DISEASE; NERVE CELL STIMULATION; NONHUMAN; PERFORANT NERVE TRACT; PRIORITY JOURNAL; RAT; RECEPTOR POTENTIAL; SPINAL CORD NERVE CELL; SYNAPSE;

ACTION POTENTIALS; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY AMINO ACID AGONISTS; FEMALE; HIPPOCAMPUS; INJECTIONS, INTRAVENOUS; MALE; NEURONS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPINAL CORD; STEREOTAXIC TECHNIQUES; SULFONAMIDES; THIOPHENES;

EID: 0034983546     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(01)00031-4     Document Type: Article

References (52)

1. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
2. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate
3. A centrally active drug that modulates AMPA receptor gated currents
4. Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation
5. Effect of AMPA receptor modulators on hippocampal and cortical function
6. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles
7. Neuropharmacology of AMPA and kainate receptors
8. A synaptic model memory: Long-term potentiation in the hippocampus
9. A glutamatergic deficiency model of schizophrenia
10. Effects of piracetam on the performance of rats in a delayed match-to-position task
11. Long term potentiation in the hippocampus: Mechanisms of initiation and modulation by neurotransmitters
12. Excitatory amino acid receptors in the vertebrate nervous system
13. Nootropic drugs positively modulate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-sensitive glutamate receptors in neuronal cultures
14. A profile of behavioral changes produced by facilitation of AMPA-type glutamate receptors
15. SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs
16. Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro
17. Long-term potentiation in the hippocampus using depolarizing current pulses as the conditioning stimulus to single volley synaptic potentials
18. Facilitative effects of the ampakine CX516 on short-term memory in rats: Enhancement of delayed-nonmatch-to-sample performance
19. Enhancement by an ampakine of memory encoding in humans
20. Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus
21. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam
22. Synergistic interactions between ampakines and antipsychotic drugs
23. Electrophysiology of hippocampal neurons II. After-potentials and repetitive firing
24. The novel AMPA receptor potentiator, LY392098, enhances spatial learning and memory in a water maze
25. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders
26. Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders
27. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders
28. Antidepressant-like actions of an AMPA receptor potentiator (LY 392098)
29. Stereoselective effects-of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies
30. 2+ of NMDA responses in spinal cord neurones
31. Novel AMP receptor potentiators LY392098 and LY404187: Effects on recombinant human AMPA receptors in vitro
32. A "long-term-potentiation-like" facilitation of hippocampal synaptic transmission induced by the nootropic nefiracetam
33. Magnesium gates glutamate-activated channels in mouse central neurones
34. Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl) propanoic acid (AMPA) receptors
35. Effect of nootropic drug oxiracetam on field potentials of rat hippocampal slices
36. Aniracetam augments, and midazolam ihibits, the long term potentiation in guinea-pig hippocampal slices
37. Different susceptibilities of long-term potentiations in CA3 and CA1 regions of guinea pig hippocampal slices to nootropic drugs
38. Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain
39. A peculiar form of potentiation in mossy fiber synapses
40. Glutamatergic aspects of schizophrenia
41. Modulation of the timecourse of fast EPSPs and glutamate channel kinetics by aniracetam
42. 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in Patas monkeys
43. The novel AMPA receptor potentiator, LY392098, reverses pharmacologically and age-induced memory deficits in rats
44. The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray
45. Are glutamate receptors specifically implicated in some forms of memory processes?
46. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders
47. Modulation of excitatory synaptic transmission by drugs that reduce desensitization at AMPA/kainate receptors
48. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons
49. Modulating excitatory synaptic neurotransmission: Potential treatment for neurological disease?
50. [3H]-benzamidophenylpropylsulfonamide-2: A novel, potent AMPA receptor potentiator and radioligand